Education
About Us
Working with TipRanks
Follow Us
Cue Health (HLTHQ)
OTHER OTC:HLTHQ
Top Page
Cue Health
(OTC:HLTHQ)
38Underperform
Cue Health (HLTHQ) vs. S&P 500 (SPY)
Market Cap
$159.00
Dividend YieldN/A
Average Volume (3M)1.79K
Price to Earnings (P/E)―
Beta (1Y)124.89
Revenue Growth-82.90%
EPS Growth-9.02%
CountryUS
Employees479
SectorHealthcare
Sector Strength78
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)-2.13
Shares Outstanding159,091,810
10 Day Avg. Volume3,441
30 Day Avg. Volume1,791
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cue Health Business Overview & Revenue Model
Company DescriptionCue Health (HLTHQ) is a healthcare technology company that focuses on providing innovative diagnostic solutions. The company operates within the medical diagnostics sector and is primarily known for its Cue Health Monitoring System, which delivers real-time, laboratory-quality health information directly to consumers. Cue Health aims to empower individuals with actionable health insights, enabling better decision-making and preventive care.
How the Company Makes MoneyCue Health generates revenue through the sale of its diagnostic products and services. The company's primary revenue stream comes from the sales of its Cue Health Monitoring System and related test cartridges, which are designed to detect various health indicators and conditions. Additionally, Cue Health may engage in partnerships with healthcare providers, enterprises, and government entities to expand its diagnostic offerings and reach broader markets. The company might also derive income from subscription-based models for its digital health platform, offering personalized health insights and data management solutions.
Cue Health Financial Statement Overview
Summary
Cue Health is facing severe financial challenges with a significant revenue decline, deeply negative profit margins, and cash flow issues. Despite these challenges, the company maintains a strong equity ratio, providing some financial stability.Income Statement
Cue Health has experienced significant revenue decline with a 85.3% decrease in 2023 compared to 2022. The company is operating at a loss with a negative gross profit margin of -79.1% and a net profit margin of -526.5%, indicating severe profitability challenges. EBIT and EBITDA margins are also deeply negative, reflecting operational inefficiencies.35
Negative
Balance Sheet
The balance sheet shows high debt levels with a debt-to-equity ratio of 0.19, which is manageable but reflective of some financial risk. Stockholders' equity has decreased, indicating financial strain. However, the equity ratio remains relatively strong at 73.6%, suggesting the company maintains a strong equity base relative to its total assets.50
Neutral
Cash Flow
Free cash flow has improved slightly with a 10.2% growth rate from 2022 to 2023, but the operating cash flow to net income ratio is negative, indicating cash flow challenges. The company is burning cash, as seen in its negative free cash flow to net income ratio, highlighting liquidity concerns.40
Negative
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 70.94M | 483.48M | 618.11M | 22.95M | 6.63M | Gross Profit |
| -56.16M | 153.50M | 341.56M | 8.00M | 6.63M | EBIT |
| -296.71M | -203.63M | 190.22M | -45.13M | -20.77M | EBITDA |
| -311.23M | -148.28M | 166.80M | -39.50M | -16.75M | Net Income Common Stockholders |
| -373.46M | -194.06M | 33.11M | -47.35M | -20.61M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 81.69M | 242.33M | 423.71M | 127.58M | 14.33M | Total Assets |
| 339.79M | 694.58M | 940.06M | 316.33M | 27.36M | Total Debt |
| 47.94M | 54.99M | 59.50M | 19.81M | 7.25M | Net Debt |
| -32.95M | -187.34M | -364.21M | -107.77M | -7.08M | Total Liabilities |
| 89.53M | 118.09M | 233.31M | 241.41M | 11.79M | Stockholders Equity |
| 250.25M | 576.49M | 706.75M | 74.92M | 15.57M |
| Cash Flow | Free Cash Flow | |||
| -157.61M | -175.55M | -125.17M | 14.39M | -16.05M | Operating Cash Flow |
| -137.81M | -112.52M | -9.45M | 92.54M | -13.10M | Investing Cash Flow |
| -19.80M | -63.03M | -115.72M | -78.15M | -2.94M | Financing Cash Flow |
| -3.03M | -5.83M | 419.62M | 100.36M | 3.72M |
Cue Health Risk Analysis
Cue Health disclosed 92 risk factors in its most recent earnings report. Cue Health reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cue Health Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $19.21B | 22.91 | 13.24% | 1.71% | 6.70% | 2.56% | |
79 Outperform | $237.85B | 17.96 | 30.95% | 1.63% | 4.59% | 134.50% | |
52 Neutral | $252.82M | 25.27 | -4.64% | ― | -54.17% | -135.78% | |
51 Neutral | $876.57M | ― | -17.15% | ― | 12.15% | 61.33% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
46 Neutral | $2.61B | ― | -50.74% | ― | -7.03% | -20233.78% | |
38 Underperform | $159.00 | ― | -149.24% | ― | -82.90% | -9.02% |
* Healthcare Sector Average
Performance Comparison
HLTHQ
Cue Health
0.04
-0.22
-84.62%
ABT
Abbott Laboratories
132.66
14.31
12.09%
MYGN
Myriad Genetics
10.25
-11.32
-52.48%
OSUR
Orasure Technologies
3.38
-3.68
-52.12%
DGX
Quest Diagnostics
168.15
41.09
32.34%
QDEL
QuidelOrtho
37.29
-9.53
-20.35%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.